A Japanese venture-led team has successfully bred three genetically modified pigs for use in human organ and cell transplants for the first time in Japan, which is struggling with donor shortages, the company said Tuesday.
But the safety of such cross-species transplantation will be investigated with further animal testing for the time being, said the venture called PorMedTec Co. that was launched based on the research of the Meiji University International Institute for Bio-Resource Research.
The team including members from U.S. biotechnology company eGenesis bred the pigs, born Sunday, using cells supplied by the U.S. company in September that had 10 different genes modified to resist rejection by the human body, PorMedTec said in a release.
Fertilized eggs, produced in October using somatic cell cloning technology to create genetically identical individuals, were transplanted into the uterus of a surrogate mother pig. The three piglets were born by Caesarean section.
Once it has been confirmed that they are growing, the pigs will be donated to scientific institutes in Japan for use in research on organ transplants to other animals such as monkeys.
"I hope to use this as an opportunity to consider the challenges of human organ transplants," said PorMedTec founder and Chief Scientist Hiroshi Nagashima in the release.
It is hoped that animal-to-human cell and organ transplants, known as xenotransplantation, will provide a solution for the shortage of organ donors.
Japan currently has around 16,000 people registered as waiting for organ donations, although only about 3 percent receive them each year, according to the Japan Organ Transplant Network.
Transplantation of pig pancreatic islet cells into patients with type 1 diabetes and a temporary transplant of a pig kidney into a fetus with severe kidney disease are planned in Japan, though such procedures have not been carried out before.